Novartis (NVS)

Health Care · Pharma & Biotech · Switzerland
$160.80
-0.14%
YTD return by year →Earnings →
About
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Source: Yahoo Finance
Sector
Healthcare
Website
www.novartis.com
Index Benchmarks
PeriodNVSDow JonesNasdaqS&P 500
1D-0.19%-1.09%(+0.9)-2.86%(+2.7)-1.82%(+1.6)
1W+6.40%-0.85%(+7.3)-2.00%(+8.4)-0.57%(+7.0)
1M+14.00%+1.66%(+12.3)-5.34%(+19.3)-1.13%(+15.1)
YTD+16.06%+7.00%(+9.1)+9.47%(+6.6)+10.52%(+5.5)
1Y+29.89%+8.85%(+21.0)+7.22%(+22.7)+10.82%(+19.1)
Numbers in parentheses show out/underperformance vs the index
Previous Close$161.10
Open$162.53
Day's Range$160.42 - $164.06
52 Week Range$122.86 - $170.46
Volume3.15M
Avg. Volume2.05M
Market Cap$307B
Beta (5Y)0.47
P/E Ratio30.6x
EPS$5.24
P/B Ratio8.24x
Dividend Yield2.97%
Revenue$57B
Net Income$10B
Operating Margin25.2%
Total Debt$48B
Cash$9.0B
1y Target Est$154.80